Intro
Foreword
Contents
Contributors
Chapter 1: Introduction: Integration of APP into Urologic Oncology Practice
Part I: Prostate Cancer
Chapter 2: Overview and Active Surveillance of Prostate Cancer
Introduction
Epidemiology
Risk Factors
Signs and Symptoms
PSA and Screening
Diagnostic Evaluation
Pathology
Staging
Risk Stratification
Active Surveillance
Bibliography
Chapter 3: Monitoring and Managing Men Following Initial Treatment of Prostate Cancer
Introduction
Monitoring Categories
Monitoring for Biochemical Recurrence

Risk Stratification and Additional Testing
Evidence of Recurrence
Conclusion
References
Chapter 4: Radical Prostatectomy and Survivorship After Radical Prostatectomy
Radical Prostatectomy
Survivorship after Radical Prostatectomy
Urinary Recovery
Sexual Recovery
Works Cited
Chapter 5: Multimodal Treatment Plans in Prostate Cancer
Introduction
Postoperative Radiation Therapy
Genomics
Bibliography
Chapter 6: Radiotherapy for Prostate Cancer
Radiotherapy Techniques
External Beam Radiation Therapy
Brachytherapy

Radiation Therapy Based on Prostate Cancer Staging
Fractionation Schedules and Dosing
Moderate Hypofractionation
Ultrahypofractionated Regimens
Accuracy
Palliative Radiation Therapy
Use of Androgen Deprivation Therapy (ADT) with Radiotherapy
Unfavorable Intermediate-Risk Disease
High-Risk and Very-High-Risk Disease
Possible Side Effects
Unique Toxicities: Recognition, Treatment, and Management
Fatigue
Urinary Toxicities
Gastrointestinal Toxicities
Sexual Dysfunction
Stress Fractures
Methods of Minimizing Adverse Effects

Survivorship after Radiotherapy
Urinary Recovery
Sexual Recovery
Bowel Toxicity
Secondary Malignancies
Other Survivorship Considerations
Assessing for Recurrence
Conclusion
References
Chapter 7: Androgen Deprivation Therapy
Introduction
Mechanism of Action
Regulation of Androgen Production
Agents of Treatment
Removal of Sources of Androgens
Use of LHRH Agonists and GnRH Antagonists
Antiandrogens: Nonsteroidal and Steroidal Antiandrogens
Antiandrogen Withdrawal
Side Effects Management
Healthy Lifestyle
Patient Counseling

Second-Line Hormone Manipulation
Ketoconazole
References
Chapter 8: Second-Generation Androgen-Targeted Agents
Second-Generation Androgen-Targeted Agents
Usage, Indications, and Side Effects of Abiraterone, Enzalutamide, Apalutamide, and Darolutamide
Abiraterone (ZYTIGA™, YONSA™)
Enzalutamide (XTANDI™)
Apalutamide (ERLEADA™)
Darolutamide (NUBEQA™)
Conclusion
References
Chapter 9: Chemotherapy and Prostate Cancer
Introduction
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Metastatic Castration-Resistant Prostate Cancer (mCRPC)